Clinical Trial Update: A Multicenter, Clinical Study of FOLFOXIRI With Bevacizumab As First-line Therapy in Patients With mCRC [Phase 2]

View source ↗

Summary

A Phase 2 multicenter trial evaluating first-line FOLFOXIRI plus bevacizumab in metastatic colorectal cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: EPS Corporation | Conditions: Colorectal Neoplasms | Phase 2 | Status: COMPLETED